Risk management : a European regulatory perspective

Area of Science:

• Pharmacovigilance and Regulatory Science
• Public Health Risk Assessment
• Medicinal Product Safety

Background:

• European regulators define risk management as a core component of pharmacovigilance.
• Minimizing risks associated with medicinal substances is a key objective for European Union citizens.
• Current practices involve detection, assessment, risk reduction, and monitoring of control measures.

Purpose of the Study:

• To outline the essential components of risk management for European regulators.
• To emphasize the integration of pharmacovigilance activities for minimizing drug-related risks.
• To highlight improvements in planning, information utilization, and regulatory action audits.

Main Methods:

• Systematic review of European regulatory frameworks for risk management.
• Analysis of pharmacovigilance strategies and their effectiveness.
• Evaluation of information tools and audit processes in regulatory action.

Main Results:

• Risk management encompasses risk detection, assessment, mitigation, and monitoring.
• Formal product risk-management plans facilitate earlier and improved pharmacovigilance planning.
• Enhanced information tools and routine audits improve the protection of public health.

Conclusions:

• Effective risk management is crucial for minimizing risks of medicinal substances in the EU.
• Proactive planning and continuous monitoring are key to successful pharmacovigilance.
• Regulatory actions require regular audits to ensure sustained effectiveness in safeguarding public health.